LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 325 filers reported holding LIGAND PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.44 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $9,000 | -90.8% | 67 | -81.2% | 0.00% | -88.9% |
| Q3 2018 | $98,000 | +32.4% | 357 | 0.0% | 0.03% | +17.4% |
| Q2 2018 | $74,000 | -97.2% | 357 | -97.8% | 0.02% | -97.2% |
| Q1 2018 | $2,638,000 | +27.8% | 15,970 | +5.9% | 0.83% | +23.0% |
| Q4 2017 | $2,064,000 | +3.3% | 15,075 | +2.7% | 0.68% | -6.9% |
| Q3 2017 | $1,999,000 | +16.0% | 14,680 | +3.4% | 0.73% | +6.3% |
| Q2 2017 | $1,724,000 | +16.3% | 14,204 | +1.4% | 0.68% | +14.2% |
| Q1 2017 | $1,483,000 | +9.1% | 14,011 | +4.8% | 0.60% | -6.5% |
| Q4 2016 | $1,359,000 | +3.3% | 13,374 | +3.7% | 0.64% | -3.5% |
| Q3 2016 | $1,316,000 | +29.8% | 12,896 | +51.8% | 0.66% | +27.6% |
| Q2 2016 | $1,014,000 | +20.9% | 8,498 | +8.5% | 0.52% | +1.4% |
| Q1 2016 | $839,000 | -36.2% | 7,832 | -35.4% | 0.51% | -57.3% |
| Q4 2015 | $1,315,000 | +32.4% | 12,127 | +4.6% | 1.20% | +1.9% |
| Q3 2015 | $993,000 | -15.9% | 11,599 | -0.9% | 1.18% | +4.4% |
| Q2 2015 | $1,181,000 | – | 11,708 | – | 1.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 2,626,160 | $138,136,000 | 24.17% |
| KNOTT DAVID M | 1,292,566 | $67,988,972,000 | 13.87% |
| GROW Partners, LLC | 200,000 | $10,520,000 | 6.41% |
| Opaleye Management Inc. | 90,000 | $4,860,000,000 | 3.82% |
| OBERWEIS ASSET MANAGEMENT INC/ | 213,317 | $11,220,000 | 2.72% |
| First Light Asset Management, LLC | 60,242 | $3,169,000 | 2.69% |
| Timpani Capital Management LLC | 98,956 | $5,205,000 | 2.59% |
| Iguana Healthcare Management, LLC | 75,000 | $3,945,000 | 2.25% |
| Eventide Asset Management | 134,400 | $7,069,000 | 2.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 215,223 | $11,321,000 | 2.16% |